<DOC>
	<DOCNO>NCT02096081</DOCNO>
	<brief_summary>The purpose study show two FDA-approved botulinum toxin drug call Xeomin速 Botox速 reduce severity vertical line ( wrinkle ) appear eyebrow ( glabellar frown line ) .</brief_summary>
	<brief_title>The Treatment Glabellar Frown Lines</brief_title>
	<detailed_description>This prospective , multicenter , randomize , double-blind , parallel group clinical study investigate equivalence incobotulinumtoxinA ( Xeomin速 ) onabotulinumtoxinA ( Botox速 ) treatment glabellar frown line .</detailed_description>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Outpatient female 18 50 year age Moderate severe glabellar frown line Glabellar Frown Lines rest rating 3 4point Facial Wrinkle Scale Previous treatment botulinum toxin Previous treatment biodegradable filler glabellar area within last 12 month Any severe uncontrolled systemic disease , malignant tumor , medical history HIV infection Known hypersensitivity incobotulinumtoxinA onabotulinumtoxinA excipients Intake forbidden concomitant medication agent might interfere neuromuscular function might interfere action botulinum toxin type within 14 day prior injection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glabellar Frown Lines</keyword>
	<keyword>Frown Lines</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>